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Background: Extracellular volume (ECV) by T1 mapping requires the contrast agent 
distribution to be at equilibrium. This can be achieved either definitively with a primed 
contrast infusion (infusion ECV), or sufficiently with a delay post bolus (bolus-only ECV). 
For large ECV, the bolus-only approach measures higher than the infusion ECV, causing 
some uncertainty in diseases such as amyloidosis. 
Purpose: To characterise the relationship between the bolus-only and current gold-standard 
infusion ECV in patients with amyloidosis. 
Study Type: Bolus-only and infusion ECV were prospectively measured. 
 
Population: 186 subjects with systemic amyloidosis attending our clinic and 23 subjects with 
systemic amyloidosis who were participating in an open-label, two-part, dose-escalation, 
phase 1 trial. 
Field Strength: Avanto 1.5T, Siemens Medical Solutions, Ehrlangen, Germany 
Assessment: Bolus-only and infusion ECV were measured in all subjects using ShMOLLI 
T1 mapping sequence.  
Statistical Tests: Pearson correlation coefficient (r). Bland-Altman. Receiver Operating 
Characteristic (ROC) curve analysis. Linear regression model with a fractional polynomial 
transformation.  
Results: The difference between the bolus-only and infusion myocardial ECV increased as 
the average of the two measures increased, with the bolus-ECV measuring higher. For an 
average ECV of 0.4, the difference was 0.013. The 95% limits of agreement for the two 
methods, after adjustment for the bias were ± 0.056. However, cardiac diagnostic accuracy 
was comparable (bolus-only vs infusion ECV AUC=0.839 vs 0.836), as were correlations 
with other clinical cardiac measures, and, in the trial patients, the ability to track changes in 
the liver/spleen with therapy. 
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Conclusions:  In amyloidosis, with large ECVs, the bolus-only technique reads higher than 
the infusion technique, but clinical performance by any measure is the same. Given the work-
flow advantages, these data suggest the bolus-only approach might be acceptable for 
amyloidosis, and might support its use as a surrogate endpoint in future clinical trials. 
Keywords: Amyloidosis, magnetic resonance imaging, myocardial extracellular volume, 





Systemic amyloidosis is a group of rare diseases characterized by amyloid deposition 
within the extracellular space[1]. Cardiac involvement is the main driver of prognosis [2], 
and is common in the two most prevalent forms of systemic amyloidosis, immunoglobulin 
light-chain amyloidosis (AL) and transthyretin amyloidosis (ATTR). The extent or severity of 
cardiac involvement in amyloidosis can be described by ventricular wall thickness, systo-
diastolic dysfunction and the degree of transmurality of late gadolinium enhancement in 
magnetic resonance imaging (MRI) imaging [3], but none of these techniques provide a 
quantitative estimate of the amyloid deposits.  
The burden of amyloid deposition can be quantified non-invasively with T1 mapping 
by cardiovascular magnetic resonance [2]. T1 mapping measures myocardial longitudinal 
magnetic relaxation, and can be performed before and after infusion of a gadolinium-based 
contrast agent. The contrast agent distributes to the extracellular space and blood plasma such 
that the relative contrast signal changes measure the myocardial extracellular volume fraction 
[4]. This measurement assumes that the distribution of the contrast agent within blood and 
myocardium is at equilibrium, established by the administration of a primed slow intravenous 
contrast infusion. However, this technique is complex and time-consuming.   
An alternative approach involves approximation of the ECV utilizing the dynamic 
equilibration achieved by delayed post-bolus measurement [5]. This bolus-only technique has 
proven to be sufficient across a wide range of cardiac diseases[6], with advantages of speed 
and simplicity. However, there is an increasing bias between results of the bolus and infusion 
techniques in pathologies characterized by higher ECV, such as amyloidosis or the zone of a 
myocardial infarct [6]. Understanding the relationship between the two techniques for 
measuring ECV would be advantageous in order to apply the simpler bolus-only ECV 
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method to large clinical populations and imminent clinical trials of treatments created to 
eliminate amyloid deposits [7, 8]. 
The aims of the study were to: (1) characterise the relationship between the bolus-
only and current gold-standard infusion cardiac ECV measurements in patients with 
amyloidosis and quantify the level of agreement between the two techniques; (2) compare the 
bolus and infusion ECV techniques in terms of: (a) cardiac diagnostic accuracy; (b) 
correlation with clinical cardiac measures; (c) reproducibility in the heart; and (d) ability to 





Bolus and infusion ECV measurements were performed in 2 distinct cohorts: 186 
subjects with systemic amyloidosis  (67 with AL and 119 ATTR amyloidosis) potentially 
involving the heart (cohort 1), and in 23 subjects with systemic amyloidosis (12 AL, 5 AFib, 
3 ATTR, 2 AA and 1 with ApoA1 amyloidosis) variously involving the heart, liver and 
spleen who were participating in an open-label, dose-escalation, phase 1 trial that included 
repeated MRI assessments (cohort 2). Both cohorts were used to characterise the relationship 
between bolus and infusion cardiac ECV measurements. The first cohort was used to 
compare the two techniques in terms of cardiac diagnostic accuracy and correlation with 
other clinical cardiac measures. The second cohort was used to compare the two techniques 
in terms of reproducibility of the cardiac ECV measure and the ability to track changes in 
amyloid load in the liver and spleen in response to treatment. 
Cohort 1. A total of 186 patients were classified into different groups: (1) 67 patients 
with biopsy proven systemic  AL amyloid (40 male; aged 61±11 years); (2) 119 with ATTR 
amyloidosis (95 male; aged 71±11years). Comparison of cardiac diagnostic accuracy, 
correlation with other clinical cardiac measures and quantification of level of agreement 
between bolus and infusion cardiac ECV have been assessed.  Cardiac involvement was 
defined according to international consensus criteria as previously described [9] [10]. Patients 
with contraindication to contrast MRI examination, glomerular filtration rate <30 mL/min 
and/or MRI incompatible devices, were excluded from the study. The research received 
approval from UCL/UCLH Joint Committees on the Ethics of Human Research Committee. 
All participants provided written informed consent.  Bolus and infusion cardiac ECV 
measures for all patients were included in the assessment of cardiac diagnostic accuracy, 
correlation with other clinical cardiac measures and the model to characterize the relationship 
between bolus and infusion cardiac ECV. 
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Cohort 2. A total of 23 systemic amyloidosis patients were enrolled in to an open-
label, two-part, dose-escalation, phase 1 trial assessing the safety and pharmacodynamics of 
R-1-[6-[R-2-carboxy-pyrrolidin-1-yl][6]-6-oxo-hexanoyl] pyrrolidine-2-carboxylic acid 
(CPHPC ) co-administered with a fully humanized monoclonal IgG1 anti-serum amyloid P 
component (SAP) monoclonal antibody (12 AL, 5 AFib, 3 ATTR, 2 AA and 1 with ApoA1 
amyloidosis; 12 male; age (mean ± sd): 59±8 years) [7]. These patients were analysed by: 
comparison of reproducibility of bolus and infusion cardiac ECV; comparison of ability of 
bolus and infusion ECV to track changes in amyloid load in the liver and spleen in response 
to treatment; quantification of level of agreement between bolus and infusion cardiac ECV. 
MRI and SAP scintigraphy assessments were both performed at baseline and on day 42 and 
subjects had both bolus and infusion ECV measured in the heart, liver and spleen 
(ClinicalTrials.gov Identifier: NCT01777243).   
All 23 subjects were included in the model to characterize the relationship between 
the bolus and infusion cardiac ECV measures.  Subjects with both bolus and infusion ECV 
measures available and involvement in the organ of interest were included in the comparison 
of each techniques’ ability to track changes in amyloid load (liver: n=9; spleen: n=13).  
Changes in liver and spleen were presented based on subjects’ first and second 
pharmacologically-active dosing sessions respectively. Results from 22 subjects (out of 23) 
of the first dosing session in which subjects had both a baseline and day 42 cardiac ECV 
measure available were included in the assessment of reproducibility of both cardiac ECV 
measures (bolus-only: n=22; infusion: n=22). One subject was excluded from the assessment 
of reproducibility, as there was preliminary evidence of clearance of cardiac amyloid.    
MRI protocol. All scans were performed on a 1.5T cardiac-enabled magnetic 
resonance imaging scanner (Avanto, Siemens Medical Solutions, Ehrlangen, Germany). 
Every patient received an initial contrast bolus of Gadoterate meglumine (gadolinium-DOTA, 
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marketed as Dotarem, Guerbet S.A., Paris, France) at a dose of 0.1 mmol/kg followed by 
measurement of the bolus only ECV (at 15 minutes), and a second contrast infusion of 0.1 
mmol/kg started after a 15-min delay (immediately after post contrast T1 image acquisition) 
at 0.0011 mmol/kg/min for a minimum of 30 min. After a minimum of 30 min of infusion, 
ECV has been measured[6]. The Shortened Modified Look-Locker Inversion recovery 
(ShMOLLI) T1 mapping sequence was applied as previously described. Operators were 
allowed to perform standard cardiac planning with resulting variation in the following image 
acquisition parameters[11]: Number of Phase Encoding Steps = 105 ± 11 range = 74 to 143 
median = 101 ms; TE = 0.5*TR = 1.06 ± 0.01 range = 0.99 to 1.07 median = 1.07 ms; 
Percent phase field of view = 73 ± 8, range = 51.04 to 98.96, median = 69.79; Acquisition 
matrix = 192 by 140 ± 15, range = 98 to 190, median = 134; Phase partial Fourier 6/8; Slice 
thickness = 8 ± 0, range = 5 to 8, median = 8 mm; Minimum TI = 103 ± 5, range = 95 to 125, 
median = 100 ms, TI increment = 80 ± 0 ms. Imaging was performed with SSFP using flip 
35° angle. Each image readout was preceded by 5 ramp up LISA pulses, and followed by a 
single 17.5° pulse at a TR/2 distance. Inversions were performed using a 10ms hyperbolic 
secant pulse.  
MRI Analysis. A single region of interest (ROI) was drawn for each of the 4 required 
parameters for ECV as previously described (Figure 1): pre and post contrast T1 
(myocardium, liver and spleen) and pre and post contrast blood T1 [12, 13]. All image 
analyses were performed blinded to the technique of ECV measurement. Hematocrit of all the 
patients was taken before each MRI study. The ECV was calculated with each method as: 
ECV = (1 - hematocrit) x ( ΔR1myocardium/liver/spleen / ΔR1blood ), where R1 = 1/T1. 
SAP scintigraphy acquisition and analysis. All patients in cohort 2 underwent 
whole body anterior and posterior scintigraphic imaging 24 h after administration of 123I-
labeled serum amyloid P component (SAP) using a GE Infinia Hawkeye gamma camera (GE 
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Healthcare, Iowa, MN) [14]. The labelled SAP studies were interpreted by a panel of 
physicians with experience of over 30,000 SAP scans. The amyloid load was categorised 
according to the intensity of 123I-SAP uptake in the organs and the residual blood-pool signal 
at 24 hours after tracer injection. The categories of amyloid load were as follows: small 
(definite organ uptake but substantial blood-pool signal), moderate (more intense organ 
localization and reduced blood-pool signal), and large (very strong organ localization with 
little or no blood-pool activity) [14-20]. SAP scintigraphy was performed at baseline and on 
day 42. Changes from baseline in amyloid load were classified as better, stable or worse.  
Statistical analysis. All analyses were performed post hoc using R version 3.2.3 (Vienna, 
Austria). The correlation between cardiac ECV and other clinical cardiac measures was 
assessed using the Pearson correlation coefficient (r). The level of agreement between the two 
techniques in measuring cardiac ECV and the repeatability of each technique was assessed 
using Bland-Altman methods[21]. A linear regression model with a fractional polynomial 
transformation was used to characterise the relationship between the difference and the 
average of the two measures of cardiac ECV and to quantify the 95% limits of agreement for 
the two methods [22].  
Receiver Operating Characteristic (ROC) curve analysis was used to compare the diagnostic 
performance of the two techniques. Discrimination of cardiac involvement using bolus-only 
ECV and infusion ECV was quantified using the area under the ROC curve (AUC), where an 
AUC of 1 indicates perfect discrimination and an AUC of 0.5 indicates no better 
discrimination than that achievable by chance. 
Box plots of subjects’ bolus and infusion ECV measurements in the liver and spleen were 
presented by organ amyloid load (none, small, moderate, large) at baseline, as assessed by 
SAP scintigraphy. In addition, individual changes in bolus and infusion ECV measures in the 
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ECV comparison. There was a strong correlation between the cardiac ECV measures from 
the two techniques (r2=0.977, 95%CI: 0.970 to 0.982) (Figure 2, left panel). The difference 
between the two cardiac ECV measures increased as the average of the two measures 
increased, with the bolus-only technique measuring higher (Figure 2, right panel).  For an 
average ECV of 0.4 across the two measures, the difference was 0.013. This difference (i.e. 
bias) increased to 0.029, 0.054, 0.088, 0.134 for an average ECV of 0.5, 0.6, 0.7 and 0.8 
respectively.   
This relationship was best characterised using a linear regression with a cubic transformation 
on the average cardiac ECV. The 95% limits of agreement after adjustment for the bias were 
+/-0.056. 
Correlation with clinical cardiac measures and cardiac diagnostic accuracy. Bolus and 
infusion ECV showed similar correlation with relevant clinical cardiac measures (Table 1). 
The ability to identify patients with cardiac amyloidosis was similar for both techniques 
(bolus-only ECV: AUC=0.839, 95% CI=0.765 to 0.913; infusion ECV: AUC=0.836, 95% 
CI=0.760 to 0.912; n=185 (Figure 3).  
Reproducibility.  Better within-subject reproducibility was observed for the bolus cardiac 
ECV measure versus the infusion measure, with 95% repeatability bounds of 0.003 ± 0.036 
(i.e. -0.033 to 0.039) and -0.006 ± 0.048 (i.e. -0.054 to 0.042) for bolus and infusion cardiac 
ECV respectively (Figure 4). 
Tracking treatment response. Large amyloid loads as assessed by SAP scintigraphy were 
associated with an increasing trend in ECV measures in both the liver and spleen for both 
techniques, however this observation was made in a small sample of patients. Median bolus-
only liver ECV measures were 0.350 (n=9), 0.395 (n=2) and 0.450 (n=8) for subjects with no, 
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moderate and large liver amyloid loads respectively. Similarly, the median bolus-only spleen 
ECV measures were 0.337 (n=4), 0.330 (n=7) and 0.575 (n=8) for subjects with small, 
moderate and large spleen amyloid loads respectively. Median infusion ECV values for both 
the liver and spleen were similarly greater for patients with larger amyloid loads (Figure 5).  
In patients with significant reduction in amyloid load in the liver (n=4) and spleen (n=4), as 
confirmed by SAP scintigraphy, comparable reductions were observed with the bolus and 
infusion ECV techniques, however this observation was made in a small sample of patients 
(Figure 6)  
 13 
DISCUSSION  
In cardiac amyloidosis, as expected [6], the bolus-only technique read higher than the 
infusion technique at high amyloid burdens. However, despite this bias both measures have 
comparable levels of discriminatory ability, correlate well with other clinical cardiac 
measures and offer the same ability to track reduction of amyloid in the liver and spleen with 
therapy. In addition, superior reproducibility was observed with bolus cardiac ECV compared 
with infusion cardiac ECV.  
Our results support the implementation of cardiac ECV measurements in amyloidosis 
by the bolus-only technique in clinical practice. This has the advantage over the infusion 
technique of much shorter scan acquisition times, requiring a single breath-hold acquisition 
before and ~15 minutes after the contrast agent administration (or a total of 6 breath-holds to 
cover a “whole-heart” approach). We have also demonstrated the feasibility of the technique 
in ECV measurements in the spleen and the liver, with an average increase in the acquisition 
time of only approximately 3 minutes. Advances in the post-processing component of ECV 
measurement, such as extracellular volume maps, may also facilitate the clinical utility of the 
technique. ECV maps (with and without the use of hematocrit measurement, the latter known 
as “synthetic ECV” maps [23]) are now available, offering a rapid automated approach to 
generate online pixel-wise ECV maps, enabling the clinician to obtain ECV values 
immediately after the acquisition of post-contrast T1 maps [24].  
The findings from this study might also extend beyond clinical utility. The 
development of therapies to reduce production of amyloid or enhance its clearance has gained 
substantial momentum [7, 8, 25, 26]. Several molecules are being developed that are able to 
specifically suppress amyloid production or enhance the clearance of amyloid deposits. 
However, the lack of available methods to track changes in amyloid load over time has been 
a major problem for drug development. Infusion and bolus ECV have been used as 
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exploratory endpoints in an open-label, two-part, dose-escalation, phase 1 trial assessing the 
safety and pharmacodynamics of CPHPC (a SAP depleter) followed by an anti-SAP 
monoclonal antibody [7]. In patients in whom major clearance of non-cardiac amyloid was 
demonstrated with the use of other methods, both infusion and bolus-only ECV confirmed 
that extracellular volume in the organ of interest decreased towards normal. Whilst the use of 
infusion ECV, although cumbersome, is feasible in small, phase 1 single centre trials, the 
implementation of the infusion technique in larger multicentre trials could be extremely 
challenging, highlighting the importance of these study findings.  
This study has some limitations. Whilst our results demonstrate the differences 
between the bolus and infusion ECV techniques, they do not provide the underlying reasons 
to account for them. The bolus-only technique assumes that a dynamic equilibrium occurs 
with sufficient delay post-bolus (15 minutes), because blood/myocardial exchange rate 
constants are much faster than other effects that influence blood gadolinium concentration 
(such as renal excretion). For amyloid, however, the increasing difference between the bolus 
and infusion techniques for increasing cardiac ECV values points towards additional 
processes potentially influencing the contrast kinetics, such as interaction between the 
contrast agents and amyloid deposits. A histological approach with cardiac biopsies has been 
used to validate the bolus-only technique in diffuse fibrosis. However, the patchy nature of 
amyloid deposition and hazards of biopsy pose challenges to this approach in cardiac 
amyloidosis, and the basis for the increasing difference between the two techniques for 
increasing ECV states in amyloid remains unknown. Furthermore, the study has been 
conducted in only one scanner, with no available data on the reproducibility between 
different scanners or reproducibility using different parameters. Although no data are 
available for ECV in the literature, native myocardial T1 has been proven to be a robust and 
reproducible biological parameters in large multicenter studies[11]. 
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 In conclusion, we have demonstrated the bolus-only ECV technique to be feasible and 
accurate when applied to a large patient population with cardiac amyloidosis. After 
accounting for the known bias of the bolus-only technique for increased ECV measurements 
at higher ECV levels, there remained a good level of agreement with the traditional infusion 
technique. This allows a more rapid protocol for scan acquisition that can be applied to both 
clinical practice and to the development of multi-centre clinical trials in cardiac amyloidosis.  
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Table 1: Correlation between bolus and infusion ECV with MRI and 
echocardiography metrics of cardiac function, 6 minute walk test, cardiac biomarkers 
and ECG. 
 
   Pearson correlation (95%CI) 
Characteristic N (%) 
Median (IQR: 25th to 
75th percentile) 
ECV by infusion ECV by bolus only 
LV Structure (MRI) 
LV massi (g/m2) 182 (98%) 107.86 (80.16, 137.64) 0.67 (0.58, 0.74) 0.67 (0.58, 0.74) 
LA areai (cm/m2) 179 (96%) 15.00 (12.43, 17.43) 0.45 (0.33, 0.56) 0.46 (0.34, 0.57) 
SVi (mL/ m2) 182 (98%) 40.84 (32.62, 46.42) -0.38 (-0.50, -0.25) -0.42 (-0.53, -0.29) 
LVEF (%) 183 (98%) 62.00 (50.00, 70.92) -0.55 (-0.65, -0.44) -0.61 (-0.69, -0.50) 
LV diastolic function (Echocardiogram) 
E/E 183 (98%) 13.71 (8.82, 19.25) 0.34 (0.20, 0.46) 0.32 (0.18, 0.44) 
E-deceleration time 
(msec) 
185 (99%) 178.00 (146.00, 215.00) -0.24 (-0.37, -0.01) -0.22 (-0.35, -0.08) 
6-minute walking 
distance (m) 




186 (100%) 210.00 (66.00, 441.50) 0.73 (0.652, 0.79) 0.70 (0.62, 0.77) 
Troponin T 
(pmol/L)* 
124 (67%) 0.06 (0.03, 0.08) 0.63 (0.513, 0.73) 0.60 (0.48, 0.70) 
ECG 
PR (msec) 113 (61%) 182.00 (154.00, 212.00) 0.43 (0.27, 0.57) 0.45 (0.29, 0.58) 
QRS (msec) 168 (90%) 98.00 (90.00, 120.00) 0.33 (0.18, 0.45) 0.35 (0.21, 0.47) 
ECG limb lead 
mean voltage 
173 (93%) 4.33 (3.33, 6.50) -0.31 (-0.44, -0.17) -0.31 (-0.44, -0.17) 
Note: ECG = electrocardiography, LA area = left atrial area indexed, LVi mass = left 
ventricle mass indexed, LVEF= left ventricle ejection fraction, SVi = stroke volume 
indexed.  




Figure 1. Examples of ROIs in ShMOLLI. 4-chamber: ShMOLLI (A) pre-contrast 
and (B) post-contrast with ROIs drawn in the blood and in the basal septum. 
Figure 2.  Correlation and agreement of bolus and infusion cardiac ECV measures: 
scatter plot of bolus vs infusion cardiac ECV (Panel A) and Bland-Altman 
comparison of bolus and infusion cardiac ECV measures (Panel B). 
Pearson correlation coefficient (r) = 0.977 (left panel) 
Linear regression with cubic transformation on average ECV:  
 intercept = -0.005 (95% CI: -0.011 to 0.002) 
 slope = 0.271 (95% CI: 0.236 to 0.306) 
 95% limits of agreement (after bias adjustment) = ± 0.056  
 E.g. with an average ECV of 0.50, the difference (i.e. “ECV bolus-only” 
minus “ECV infusion” is estimated as -0.005 + 0.271*(0.503) which is equal 
to 0.029 
 
Figure 3. Receiver operating characteristic (ROC) curve for the discrimination of 
cardiac amyloidosis by ECV with bolus-only technique (left panel) and ECV with 
infusion technique (right panel). 
Figure 4. Repeatability of bolus-only and infusion cardiac ECV measures. Scatter-plot 
of baseline versus day 42 follow-up bolus-only ECV (A) and infusion ECV (B). Bland-
Altman comparison of two repeat bolus (C) and infusion (D) ECV measures.  
Figure 5. Association between ECV at baseline (infusion and bolus-only techniques) 
and baseline amyloid load as assessed by SAP scintigraphy in the liver (A) and the 
spleen (B). 
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Figure 6. – Changes in liver ECV (infusion and bolus-only techniques) vs changes in 
liver amyloid load as assessed by SAP scintigraphy (Left panel); changes in spleen 
ECV (infusion and bolus-only techniques) vs changes in spleen amyloid load as 
assessed by SAP scintigraphy (Right panel).  
 
